Ítem
Acceso Abierto

Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains

Mostrar el registro sencillo de la publicación
dc.creatorMercer, Derryspa
dc.creatorWelsch, Jeremispa
dc.creatorJosa, Diego F.spa
dc.creatorHolzapfel, Marionspa
dc.creatorLebrat, Julienspa
dc.creatorCeballos Garzón, Carlos Andrésspa
dc.date.accessioned2025-07-21T16:49:41Z
dc.date.available2025-07-21T16:49:41Z
dc.date.created2025-06-01spa
dc.date.issued2025-06-01spa
dc.description.abstractThis study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the Calgary biofilm device. Mature-phase biofilms of C. albicans, C. auris (clades I, II, III, IV), and C. parapsilosis were exposed to a range of drug concentrations (0.12–128 µg/mL). Minimum Inhibitory Concentration (MIC) values for planktonic cells were ?2 µg/mL for all strains; however, biofilm-associated MICs, minimum biocidal concentration (MBC), minimum biofilm eradication (MBEC), and minimum biofilm damaging concentration (MBDC) were significantly higher (2–4,119 times). Geometric mean (GM) of MBEC values indicated that MNGX had the highest antifungal activity within Candida species, with a GM-MBEC of 5.9 µg/mL. Despite its overall potency, MNGX was less effective against C. auris biofilms from clade IV strains, where IBF showed superior activity. While not the most potent agent overall, AMB induced the smallest fold-change increases (2- to 32-fold) in biofilm-associated states data compared to planktonic MICs. Conversely, CAS exhibited the lowest activity against Candida spp. biofilms. The eradication of C. auris and C. parapsilosis biofilms required substantially higher concentrations than C. albicans, with some agents, such as RZF and CAS, necessitating up to 42-fold increases in dosage. In conclusion, our in vitro model highlights the antibiofilm activity of novel antifungals against major Candida species, revealing significant differences in efficacy among species. MNGX demonstrated the highest activity, underscoring its potential as a promising candidate for the treatment of biofilm-related infections.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1128/aac.00137-25spa
dc.identifier.issn0066-4804spa
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/46089
dc.language.isoengspa
dc.publisherAmerican Society Micrologyspa
dc.relation.ispartofAntimicrobial Agents and Chemotherapy June 2025 Volume 69 Issue 6spa
dc.relation.urihttps://journals.asm.org/doi/10.1128/aac.00137-25spa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourceAntimicrobial Agents and Chemotherapyspa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordFarmacologíaeng
dc.subject.keywordCandida biofilmseng
dc.subject.keywordAntibiofilm activityeng
dc.subject.keywordNovel antifungalseng
dc.subject.keywordCalgary biofilm deviceeng
dc.titleAntibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strainsspa
dc.typearticlespa
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionspa
dc.type.spaArtículo de Investigaciónspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Antibiofilm_activity_of_manogepix_ibrexafungerp_amphotericin_B_rezafungin_and_caspofungin.pdf
Tamaño:
1.53 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos